Importantly, treatment with SGLT2i uniformly enhanced glucose oxidation in the various tissues, and it decreased expression of hepatic CD36, suggesting that, in diabetes, SGLT2i shift TCA cycle metabolism from fatty acid to glucose oxidation. The gene discussed is CD36; the disease is diabetes mellitus.